vTv Therapeutics (NASDAQ:VTVT) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
vTv Therapeutics (NASDAQ:VTVT) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
vTv Therapeutics (NASDAQ:VTVT) was upgraded by analysts at BTIG Research to a "strong-buy" rating.
vTv Therapeutics (NASDAQ:VTVT) is now covered by analysts at BTIG Research. They set a "buy" rating and a $40.00 price target on the stock.
vTv Therapeutics (NASDAQ:VTVT) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.